Profile - To The Moon

MrK88088

Posts · 5Posts · 5
Following · 0Following · 0
Followers · 0Followers · 0

- MrK88088MrK88088
  ·2021-05-05
  QDEL should be an insurance stock in your portfolio. Although vaccination is widely propagated but the mutation is ever changing. Buy QDEL to hedge your portfolio. As long as the virus is still around the world.
  Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?
  Quidel Corporation QDEL is expected to report first-quarter fiscal 2021 results on May 6, 2021. The
  Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?
  62 Comment
  Like
  Share
  Report
- MrK88088MrK88088
  ·2021-04-28
  Covid-19 will be around for quite a while. Testing still remains essential even after vaccination drive.
  Sorry, this post has been deleted
  17 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":3552211490267635,"uuid":"3552211490267635","gmtCreate":1589118455382,"gmtModify":1712580949290,"name":"MrK88088","pinyin":"mrk88088","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/177889ab348d52aa048bc5d523f30868","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":14,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.34%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.19%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":102877126,"gmtCreate":1620201507165,"gmtModify":1704340110395,"author":{"id":"3552211490267635","authorId":"3552211490267635","name":"MrK88088","avatar":"https://community-static.tradeup.com/news/177889ab348d52aa048bc5d523f30868","crmLevel":6,"crmLevelSwitch":1},"themes":[],"htmlText":"QDEL should be&nbsp;an insurance stock in your portfolio. Although vaccination is widely propagated but the mutation is ever changing. Buy QDEL to hedge your portfolio. As long as the virus is still around the world.&nbsp;","listText":"QDEL should be&nbsp;an insurance stock in your portfolio. Although vaccination is widely propagated but the mutation is ever changing. Buy QDEL to hedge your portfolio. As long as the virus is still around the world.&nbsp;","text":"QDEL should be an insurance stock in your portfolio. Although vaccination is widely propagated but the mutation is ever changing. Buy QDEL to hedge your portfolio. As long as the virus is still around the world.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/102877126","repostId":"2133431805","repostType":2,"repost":{"id":"2133431805","pubTimestamp":1620146824,"share":"https://www.laohu8.com/m/news/2133431805?lang=&edition=full","pubTime":"2021-05-05 00:47","market":"us","language":"en","title":"Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?","url":"https://stock-news.laohu8.com/highlight/detail?id=2133431805","media":"Zacks","summary":"Quidel Corporation QDEL is expected to report first-quarter fiscal 2021 results on May 6, 2021.\nThe ","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/QDEL\">Quidel Corporation</a></strong> QDEL is expected to report first-quarter fiscal 2021 results on May 6, 2021.</p>\n<p>The company delivered an earnings surprise of 9.6% in the last reported quarter. Further, its bottom line beat estimates in each of the trailing four quarters, the average being 30.9%.</p>\n<h3>Q1 Estimates</h3>\n<p>The Zacks Consensus Estimate for total revenues of $375.2 million implies growth of 114.9% from the prior-year quarter’s reported figure. Also, the consensus mark for earnings per share (EPS) is pegged at $4.87, indicating significant growth from the prior-year quarter’s reported figure.</p>\n<h3>Factors at Play</h3>\n<p>In the last reported quarter, Quidel’s Molecular Diagnostic Solutions delivered robust results. This momentum is likely to have continued in the to-be reported quarter as well. Further, higher sales of COVID-19 products are expected to have boosted growth in the to-be-reported quarter.</p>\n<p>The company is likely to have witnessed an uptick in rapid immunoassay revenues in the fiscal first quarter on higher sales derived from the Sofia platform. Progress of this platform is expected to have been aided by an increase in Sofia SARS Antigen and Sofia Combo ABC product sales.</p>\n<p>However, Quidel witnessed a decline in its specialized diagnostic solutions revenues in the last reported quarter. This downside was due to weak respiratory products in the company’s Cell Culture business, a trend that most likely continued in the fiscal first quarter too.</p>\n<p>Also, Quidel witnessed softness in its overall Influenza revenues in the fourth quarter of fiscal 2020 due to a very low prevalence of Influenza in the period, a trend that most likely persisted in the first quarter of fiscal 2021 as well.</p>\n<p>Nonetheless, overall molecular growth of the Lyra product category is expected to have contributed to the to-be-reported quarter’s top line, possibly led by an uptick in Solana SARS revenues.</p>\n<p>In the to-be reported quarter, the company’s Cardiometabolic Immunoassay business is expected to have been driven by strength in the Triage business and the Beckman BNP business.</p>\n<p>Advancement of the COVID-diagnostic product pipeline, especially with the Sofia Serology assay, is expected to have boosted the company’s performance in the fiscal first quarter. The FDA EUA approvals to market Solana SARS and QuickVue SARS Antigen is also expected to have driven growth in the to-be reported quarter.</p>\n<div>\n<h3>Quidel Corporation Price and EPS Surprise</h3>\n<img height=\"262\" src=\"https://s1.yimg.com/uu/api/res/1.2/Hu3H2e_X6msf7uWNu.NLmQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/0ec51457a5f7db18d95f58a0cbdfd4f8\" title=\"\" width=\"539\"/>\n<p>Quidel Corporation price-eps-surprise | Quidel Corporation Quote</p>\n</div>\n<p>Quidel has been evolving within its R&amp;D and instrument systems development teams for a while now. This, in turn, is expected to reflect on its results for the fiscal first quarter. Moreover, solid momentum of the Savanna cross-functional product development team might have enhanced the company’s to-be-reported quarter’s performance.</p>\n<p>In recent times, Sofia Q, formerly named Sniffles, which is the company’s next-generation Sofia platform, is steadily gaining traction. This is also likely to have bumped up the top line in the to-be-reported quarter.</p>\n<p>Additionally, the company is expected to have consistently benefited from newer products like Sofia Lyme, TriageTrue, High Sense, Troponin assay, Triage PLGF and the new Sofia GI suite in the quarter as well.</p>\n<h3>What Our Quantitative Model Suggests</h3>\n<p>Our proven model does not predict an earnings beat for Quidel this time around. The combination of a positive  Earnings ESP  and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that is not the case here as you will see.</p>\n<p><strong>Earnings ESP:</strong> Quidel has an Earnings ESP of -2.47%. You can uncover the best stocks to buy or sell before they're reported with our  Earnings ESP Filter.</p>\n<p><strong>Zacks Rank: </strong>Quidel carries a Zacks Rank #5 (Strong Sell).</p>\n<h3>Zacks Rank and Key Picks</h3>\n<p>Here are some medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.</p>\n<p><strong>AmerisourceBergen </strong>ABC has an Earnings ESP of +0.23% and a Zacks Rank of 3, currently. You can see  <strong>the complete list of today’s Zacks #1 Rank stocks here.</strong></p>\n<p><strong>DENTSPLY SIRONA </strong>XRAY has an Earnings ESP of +11.36% and is a Zacks #2 Ranked stock, presently.</p>\n<p><strong>Cerner Corporation </strong>CERN has an Earnings ESP of +0.37% and a Zacks Rank of 3 at present.</p>\n<h3>More Stock News: This Is Bigger than the iPhone!</h3>\n<p>It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.</p>\n<p>Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.</p>\n<p><strong>Click here for the 4 trades &gt;&gt;</strong></p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\nDENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report\n<br/> \n<br/>\nCerner Corporation (CERN) : Free Stock Analysis Report\n<br/> \n<br/>\nAmerisourceBergen Corporation (ABC) : Free Stock Analysis Report\n<br/> \n<br/>\nQuidel Corporation (QDEL) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuidel (QDEL) to Report Q1 Earnings: What's in the Offing?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-05 00:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/quidel-qdel-report-q1-earnings-164704357.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quidel Corporation QDEL is expected to report first-quarter fiscal 2021 results on May 6, 2021.\nThe company delivered an earnings surprise of 9.6% in the last reported quarter. Further, its bottom ...</p>\n\n<a href=\"https://finance.yahoo.com/news/quidel-qdel-report-q1-earnings-164704357.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/8qpOhG4H1El45cPbQkx24Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/fjS8E3eMtYWm5omrejEHog--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c7d7c00f4e1e615cc981c95227b4d9a3","relate_stocks":{"QDEL":"窥得儿医药","XRAY":"登士柏国际","CERN":"美国塞纳"},"source_url":"https://finance.yahoo.com/news/quidel-qdel-report-q1-earnings-164704357.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2133431805","content_text":"Quidel Corporation QDEL is expected to report first-quarter fiscal 2021 results on May 6, 2021.\nThe company delivered an earnings surprise of 9.6% in the last reported quarter. Further, its bottom line beat estimates in each of the trailing four quarters, the average being 30.9%.\nQ1 Estimates\nThe Zacks Consensus Estimate for total revenues of $375.2 million implies growth of 114.9% from the prior-year quarter’s reported figure. Also, the consensus mark for earnings per share (EPS) is pegged at $4.87, indicating significant growth from the prior-year quarter’s reported figure.\nFactors at Play\nIn the last reported quarter, Quidel’s Molecular Diagnostic Solutions delivered robust results. This momentum is likely to have continued in the to-be reported quarter as well. Further, higher sales of COVID-19 products are expected to have boosted growth in the to-be-reported quarter.\nThe company is likely to have witnessed an uptick in rapid immunoassay revenues in the fiscal first quarter on higher sales derived from the Sofia platform. Progress of this platform is expected to have been aided by an increase in Sofia SARS Antigen and Sofia Combo ABC product sales.\nHowever, Quidel witnessed a decline in its specialized diagnostic solutions revenues in the last reported quarter. This downside was due to weak respiratory products in the company’s Cell Culture business, a trend that most likely continued in the fiscal first quarter too.\nAlso, Quidel witnessed softness in its overall Influenza revenues in the fourth quarter of fiscal 2020 due to a very low prevalence of Influenza in the period, a trend that most likely persisted in the first quarter of fiscal 2021 as well.\nNonetheless, overall molecular growth of the Lyra product category is expected to have contributed to the to-be-reported quarter’s top line, possibly led by an uptick in Solana SARS revenues.\nIn the to-be reported quarter, the company’s Cardiometabolic Immunoassay business is expected to have been driven by strength in the Triage business and the Beckman BNP business.\nAdvancement of the COVID-diagnostic product pipeline, especially with the Sofia Serology assay, is expected to have boosted the company’s performance in the fiscal first quarter. The FDA EUA approvals to market Solana SARS and QuickVue SARS Antigen is also expected to have driven growth in the to-be reported quarter.\n\nQuidel Corporation Price and EPS Surprise\n\nQuidel Corporation price-eps-surprise | Quidel Corporation Quote\n\nQuidel has been evolving within its R&D and instrument systems development teams for a while now. This, in turn, is expected to reflect on its results for the fiscal first quarter. Moreover, solid momentum of the Savanna cross-functional product development team might have enhanced the company’s to-be-reported quarter’s performance.\nIn recent times, Sofia Q, formerly named Sniffles, which is the company’s next-generation Sofia platform, is steadily gaining traction. This is also likely to have bumped up the top line in the to-be-reported quarter.\nAdditionally, the company is expected to have consistently benefited from newer products like Sofia Lyme, TriageTrue, High Sense, Troponin assay, Triage PLGF and the new Sofia GI suite in the quarter as well.\nWhat Our Quantitative Model Suggests\nOur proven model does not predict an earnings beat for Quidel this time around. The combination of a positive  Earnings ESP  and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that is not the case here as you will see.\nEarnings ESP: Quidel has an Earnings ESP of -2.47%. You can uncover the best stocks to buy or sell before they're reported with our  Earnings ESP Filter.\nZacks Rank: Quidel carries a Zacks Rank #5 (Strong Sell).\nZacks Rank and Key Picks\nHere are some medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.\nAmerisourceBergen ABC has an Earnings ESP of +0.23% and a Zacks Rank of 3, currently. You can see  the complete list of today’s Zacks #1 Rank stocks here.\nDENTSPLY SIRONA XRAY has an Earnings ESP of +11.36% and is a Zacks #2 Ranked stock, presently.\nCerner Corporation CERN has an Earnings ESP of +0.37% and a Zacks Rank of 3 at present.\nMore Stock News: This Is Bigger than the iPhone!\nIt could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.\nZacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.\nClick here for the 4 trades >>\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nDENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report\n \n\nCerner Corporation (CERN) : Free Stock Analysis Report\n \n\nAmerisourceBergen Corporation (ABC) : Free Stock Analysis Report\n \n\nQuidel Corporation (QDEL) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":62,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377489453,"gmtCreate":1619553237472,"gmtModify":1704725757085,"author":{"id":"3552211490267635","authorId":"3552211490267635","name":"MrK88088","avatar":"https://community-static.tradeup.com/news/177889ab348d52aa048bc5d523f30868","crmLevel":6,"crmLevelSwitch":1},"themes":[],"htmlText":"Covid-19 will be around for quite a while. Testing still remains essential even after vaccination drive.&nbsp;","listText":"Covid-19 will be around for quite a while. Testing still remains essential even after vaccination drive.&nbsp;","text":"Covid-19 will be around for quite a while. Testing still remains essential even after vaccination drive.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/377489453","repostId":"2129649863","repostType":2,"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}